HIV Treatment Bulletin - November 2003
Polly Clayden, HIV i-Base

A report from the French Perinatal Study published in the September issue of AIDS found that perinatal exposure to zidovudine might result in a small but significant and durable effect on haematopoiesis up to the age of 18 months.

The French Perinatal Study, established in 1986, prospectively follows infected and uninfected infants born to HIV-positive mothers.

In a longitudinal study, the investigators analysed haematological variables in 4,249 infants from zero to 18 months including haemoglobin, platelets, polynuclear neutrophils, total lymphocytes, and CD4+ and CD8+ lymphocytes. To perform the analysis they used non-parametric smoothing techniques. Modeling of repeated measures and non-linear evolution with age, with models combining natural cubic B-splines and random effects.

The investigators reported a transient reduction in haemoglobin levels in newborns exposed to zidovudine. Multivariate analysis taking into account age, prematurity, geographical origin, maternal drug use and maternal CD4 cell count, indicated that levels of the three other lineages were slightly lower until age 18 months in exposed than in not exposed infants (p < 0.0001 for each lineage). They report a negative relationship between the duration of exposure and each haematological variable.

Additionally, combinations of antiretrovirals were associated with larger decreases than zidovudine monotherapy up to 15 months of age. Similar, but less pronounced, patterns were found for the CD4+ and CD8+ subpopulations of lymphocytes.

The investigators concluded: “Zidovudine administered during the perinatal period may result in a small but significant and durable effect on haematopoïesis up to the age of 18 months.” They also noted that the clinical consequence of these findings are probably minor or non-existent and: “A more detailed analysis of CD4/CD lymphocyte sub-populations (ie naïve/memory phenotype and function) could be of value as would long term evaluation.”

Ref: Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C et al. Perinatal antiretroviral treatment and haematopoiesis in HIV-uninfected infants, AIDS. 2003 Sep 26;17(14):2053-61.

031110
IB30409-27

©2003. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.